Skip to main content
Fig. 5 | Journal of Experimental & Clinical Cancer Research

Fig. 5

From: Annexin A2 contributes to cisplatin resistance by activation of JNK-p53 pathway in non-small cell lung cancer cells

Fig. 5

Annexin A2 inhibited p53 expression and cell apoptosis through JNK signaling. a A549 cells were transfected with pCMV6-Annexin A2, the expression of p-AKT, p-p38, p-JNK, p-ERK expression was analyzed by Western blot. b A549/DDP cells were transfected with Annexin A2 siRNA, the expression of p-AKT, p-p38, p-JNK was analyzed by Western blot. c-d A549 cells were transfected with pCMV6-Annexin A2, and then treated with JNK inhibitor SP600125 or/and AKT inhibitor LY294006, c the expression of p53, p-AKT, p-JNK was analyzed by Western blot; d the expression of p53 and p53-regulated apoptotic genes p21, GADD45, and BAX were measured by Real time RT-PCR. e A549 cells were transfected with pCMV6-Annexin A2, and then co-treated with SP600125 and cisplatin or co-treated with LY294006 and cisplatin, cells were stained with Annexin V-FITC and propidium iodide, and the cell apoptosis were analyzed by flow cytometry. f A549/DDP cells were transfected with Annexin A2 siRNA, and then treated with p38 inhibitor SB203580, the expression of p53 and p-p38 were measured by Western blot. *P < 0.05

Back to article page